Hizentra is a proven solution for treating primary immunodeficiency (PI), a condition that affects the immune system. But who is behind this life-saving medication? In this article, we will explore the makers of Hizentra and the science that goes into producing this important treatment. We will also look at how Hizentra has helped people with PI lead healthier and more fulfilling lives. Read on to learn more about the innovative and dedicated team that makes Hizentra a reality.
Hizentra is a prescription medicine used to treat primary immunodeficiency (PI), a condition in which the body’s immune system is not working properly. It is manufactured by CSL Behring, a global biotherapeutics leader driven by its promise to save and improve lives. Hizentra is the first and only subcutaneous immunoglobulin (SCIG) therapy indicated for routine prophylaxis to prevent infections in adults with PI. CSL Behring is committed to providing quality products, education and support to people living with PI and to healthcare professionals.
What is Hizentra?
Hizentra is a brand of immune globulin subcutaneous (SCIG) therapy prescribed to treat primary immune deficiency diseases (PIDDs). It is a form of treatment that helps to protect the body from infection by providing extra antibodies. It is administered via subcutaneous injection and is available in a variety of sizes ranging from 1 mL to 30 mL.
Hizentra is made by CSL Behring, a global biotechnology company dedicated to bringing innovative therapies to patients. CSL Behring manufactures Hizentra in Germany and distributes it to patients in the United States and other countries.
What are the Benefits of Hizentra?
Hizentra is an effective treatment for PIDDs, providing protection from infection by providing extra antibodies. It is administered via subcutaneous injection, which helps to reduce the risk of infection from contaminated needles. Additionally, it is available in a variety of sizes, making it easy to customize the dose for each patient.
What is the Recommended Dose for Hizentra?
The recommended dose of Hizentra for adults and adolescents is 20 mL every two weeks. The dose may be adjusted depending on individual needs and patient response. It is important to follow the instructions provided by your healthcare provider.
What are the Possible Side Effects of Hizentra?
The most common side effects of Hizentra include headache, nausea, abdominal pain, and redness at the injection site. Other possible side effects include joint pain, muscle pain, rash, fever, and difficulty breathing. It is important to talk to your healthcare provider about any side effects you may experience.
Frequently Asked Questions
Question 1: Who manufactures Hizentra?
Answer: Hizentra is manufactured by CSL Behring, a biotechnology company that is part of the CSL Group. CSL Behring is based in King of Prussia, Pennsylvania and is one of the world’s largest manufacturers of plasma-derived and recombinant therapies. CSL Behring is a leader in the development, production, and marketing of biotherapeutics for the treatment of rare conditions and other diseases. Hizentra is one of the products developed and manufactured by CSL Behring.
Question 2: What is Hizentra used for?
Answer: Hizentra is a subcutaneous immunoglobulin (SCIg) therapy used to help reduce the frequency and severity of symptoms in people with primary immunodeficiency (PI). PI is a rare disorder that affects the body’s ability to fight infection. Hizentra helps boost the body’s immune system by providing antibodies that help fight off infection. It can help reduce the frequency and severity of infections, and improve quality of life for people with PI.
Question 3: How is Hizentra administered?
Answer: Hizentra is administered as a subcutaneous injection, usually into the abdomen, thigh, upper arm, or buttocks. It is administered once or twice a month, depending on the dose prescribed by a healthcare provider. The injections can be given at home or in a healthcare setting.
Question 4: What are the side effects of Hizentra?
Answer: Common side effects of Hizentra include redness, itching, or pain at the injection site; headache; nausea; and muscle or joint pain. Other side effects that have been reported include rash, fever, hives, and swelling. If any of these side effects occur, it is important to contact a healthcare provider for advice.
Question 5: How long does it take for Hizentra to work?
Answer: It usually takes one to two weeks for Hizentra to start working. It is important to follow the instructions of a healthcare provider when taking Hizentra. It is also important to follow up with a healthcare provider regularly to monitor the effectiveness of Hizentra.
Question 6: Is Hizentra covered by insurance?
Answer: Hizentra is covered by most health insurance plans. It is important to check with a healthcare provider and insurance plan to determine coverage. Some insurance plans may require pre-authorization before Hizentra can be prescribed. Additionally, some insurance plans may require patients to try other treatments before they cover Hizentra.
In conclusion, Hizentra is a safe and effective immunoglobulin replacement therapy that is manufactured and distributed by CSL Behring, a leading biopharmaceutical company with a long history of providing effective treatments to people with serious and rare diseases. CSL Behring has a team of experts dedicated to providing quality products and services to ensure that Hizentra is safe and effective. With its commitment to quality, CSL Behring is the ideal choice for patients seeking a reliable and effective immunoglobulin replacement therapy.